Can peptides help me lose weight?
This is the one area where peptides have unambiguous, large-scale clinical proof. GLP-1 and GLP-1/GIP receptor agonists produce 15–23% average body-weight reduction in randomised trials — results no other drug class has matched.
Who this applies to
Problems people bring to this category
- Obesity and overweight with weight-related comorbidity
- Type 2 diabetes and insulin resistance
- Constant food preoccupation or "food noise"
- Metabolic dysfunction-associated fatty liver (MASLD)
- Cardiovascular risk reduction in established disease
Compounds studied
Peptides used for weight loss & metabolic health
Semaglutide
FDA-approvedGLP-1 agonist; ~15% mean weight loss at 68 weeks and a 20% reduction in major cardiovascular events in people with existing heart disease.
Find Semaglutide at a tested supplierTirzepatide
FDA-approvedDual GIP/GLP-1 agonist; up to ~21% mean weight loss, currently the most effective approved option.
Find Tirzepatide at a tested supplierHonest reading
What the evidence actually shows
- Weight regain is the norm after stopping: withdrawal trials show most lost weight returns within a year, so this is chronic therapy rather than a course.
- GI side effects (nausea, vomiting, constipation) affect a large minority and drive most discontinuations.
- Roughly a quarter to 40% of the weight lost is lean mass unless resistance training and adequate protein intake are maintained.
Expectation setting
What peptides will not do here
- It will not target fat in a specific body area.
- It does not remove the need for diet, protein and training if you want to keep muscle.
- Compounded or research-grade copies are not equivalent to approved products in purity or dose accuracy.
Sources
Studies behind this page
- RCT · 2021
Once-Weekly Semaglutide 2.4 mg in Adults with Overweight or Obesity
New England Journal of Medicine
- RCT · 2022
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
New England Journal of Medicine
- Phase II · 2023
Triple–Hormone-Receptor Agonist Retatrutide for Obesity
New England Journal of Medicine
- RCT · 2024
Continued Treatment with Tirzepatide vs Withdrawal on Weight Maintenance (SURMOUNT-4)
JAMA
- Meta-analysis · 2025
Body Composition Changes with GLP-1 Receptor Agonists: Lean Mass Meta-analysis
Obesity Reviews